Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368554 | 1.00 | FOLH1 (0.57) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL1711242 | 1.00 | FOLH1 (0.57) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL29511099 | 1.00 | FOLH1 (0.57) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL29563714 | 1.00 | FOLH1 (0.57) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL29405941 | 0.98 | FOLH1 (0.55) | FOLH1NOD1GSRCPB2SLC6A5 | |
| Benzene SCHEMBL28095115 | 0.97 | FOLH1 (0.54) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL11644217 | 0.97 | FOLH1 (0.54) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL11644225 | 0.97 | FOLH1 (0.54) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL29406243 | 0.95 | NOD1 (0.56) | FOLH1NOD1GSRCPB2SLC6A5 | |
| SCHEMBL29674589 | 0.95 | NOD1 (0.56) | FOLH1NOD1GSRCPB2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| CN-122028936-A | Antibody-drug conjugates | ADC疗法责任有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-02-26 | — | — | US | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | claimed |
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| US-20260014264-A1 | SPECIFIC TOPOISOMERASE INHIBITOR, USE AS ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | BIOBRICS LIFE SCIENCE (NANTONG) CO., LTD. (CN) | 2026-01-15 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| WO-2022058395-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2022-03-24 | — | — | WO | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-107936089-A | A kind of method of synthetic styrene-acrylic aminoacyl lysine dipeptides | 重庆大学 | 2018-04-20 | — | — | CN | claimed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014264-A1 | SPECIFIC TOPOISOMERASE INHIBITOR, USE AS ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | TOP1, TOP2A, TOP2B | FOLH1 68/4885NOD1 3697/4885GSR 3224/4885 |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | FOLH1 899/4885NOD1 924/4885GSR 4852/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | FOLH1 1270/4885NOD1 220/4885GSR 4135/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | FOLH1 214/4885NOD1 3543/4885GSR 3433/4885 |
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | GIPR, GLP1R, GCG | FOLH1 935/4885NOD1 458/4885GSR 958/4885 |
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | H1-3, H1-4, H1-2 | FOLH1 488/4885NOD1 4690/4885GSR 4791/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | FOLH1 62/4885NOD1 4253/4885GSR 2589/4885 |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | FOLH1 2756/4885NOD1 269/4885GSR 3726/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | FOLH1 320/4885NOD1 3411/4885GSR 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.